Methylvaline | 114416-26-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Methylvaline
• 英文别名: (3S)-3-amino-4-methylpentan-2-one
• CAS: 114416-26-1
• 化学式: C₆H₁₃NO
• 分子量: 115.175
• InChiKey: LQKJPBCCNFJUCX-LURJTMIESA-N

物化性质

• 沸点：
  155.5±23.0 °C(Predicted)
• 密度：
  0.891±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Methylvaline 、 N-A-(2,4-二硝基-5-氟苯基)-L-丙氨酸 在 碳酸氢钠 作用下， 以 水 、 丙酮 为溶剂， 生成
  参考文献：
  名称：

  Protease Inhibitors from a Water Bloom of the Cyanobacterium Microcystis aeruginosa

  摘要：

  Bioassay-guided fractionation of the polar extract of a Microcystis aeruginosa water bloom biomass yielded 10 micropeptins and one anabaenopeptin. Eight of the micropeptins, micropeptins HU1069 (1), HU989 (2), HU1021 (3), HU1041 (4), HU975 (5), HU895A (6), HU909 (7), and HU895B (8), are new, while two, micropeptins 478-A (10) and 478-B (11), were previously isolated from a bloom of M. aeruginosa from Japan. The new anabaenopeptin HU892 (9) belongs to the relatively rare subgroup, presenting an aliphatic amino acid at the carboxylic end of the peptide and N-methylhomoaromatic amino acid at the second position. The structures of the compounds were determined by ID and 2D NMR techniques and mass spectrometric data. The isolated micropeptins inhibited trypsin with IC50'S that varied between 0.7 and 5.2 mu M and unexpectedly inhibited chymotrypsin with IC50's that varied between 2.8 and 72.0 mu M. The SAR of these micropeptins is discussed.

  DOI：

  10.1021/np900340t
• 作为试剂：
  描述：

  sodium methansulfinate 、 (R)-4-(2-(1H-phenylpropane[d]imidazol-1-yl)-7-iodothieno[3,2-d]pyrimidin-4-yl)-3-methanol morpholine 在 copper(l) iodide 、 Methylvaline 作用下， 以 二甲基亚砜 为溶剂， 以48 %的产率得到(R)-4-(2-(1H-benzo[d]imidazole-1-yl)-7-(methylsulfonyl)thieno[3,2-d]pyrimidin-4-yl)-3-methylmorpholine
  参考文献：
  名称：

  CN115991716

  摘要：

  公开号：

文献信息

• [EN] BIOLOGICAL MATERIALS AND USES THEREOF<br/>[FR] MATÉRIELS BIOLOGIQUES ET LEURS UTILISATIONS
  申请人：ANTIKOR BIOPHARMA LTD

  公开号：WO2016046574A1

  公开（公告）日：2016-03-31

  The invention provides compounds comprising a therapeutic agent coupled to a carrier molecule, with a minimum coupling ratio of 5: 1; wherein the carrier molecule is (i) an antibody fragment or derivative thereof or (ii) an antibody mimetic or derivative thereof; and wherein the therapeutic agents are coupled onto a lysine amino acid residue; and further wherein the therapeutic agent is not a photosensitising agent. There is also provided uses, methods relating to such compounds, as well as processes for their manufacture.

  该发明提供了包含治疗剂与载体分子偶联的化合物，最低偶联比为5:1；其中，载体分子是(i)抗体片段或其衍生物，或(ii)抗体模拟物或其衍生物；治疗剂偶联到赖氨酸氨基酸残基上；进一步，治疗剂不是光敏剂。还提供了关于这些化合物的用途、方法以及其制造过程。
• Hepatitis C Virus Inhibitors
  申请人：Belema Makonen

  公开号：US20100080772A1

  公开（公告）日：2010-04-01

  The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及化合物、组合物和治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这些化合物的药物组合物以及使用这些化合物治疗HCV感染的方法。
• [EN] BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2010017401A1

  公开（公告）日：2010-02-11

  The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及化合物、组合物和治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这些化合物的药物组合物以及在治疗HCV感染中使用这些化合物的方法。
• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：ENANTA PHARM INC

  公开号：WO2010099527A1

  公开（公告）日：2010-09-02

  The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了抑制RNA含病毒，特别是丙型肝炎病毒（HCV）的化合物或药用可接受的盐、酯或前药，因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY
  申请人：Baker William R.

  公开号：US20090318396A1

  公开（公告）日：2009-12-24

  New chemical entities which comprise corticosteroids and phosphorylated β-agonists for use in therapy and compositions comprising and processes for preparing the same.

  新的化学实体包括皮质类固醇和磷酸化的β-激动剂，用于治疗以及包含这些化学实体的组合物和制备它们的方法。